# Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

> **NCT00406276** · PHASE1,PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 28 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** RAD001
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00406276
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2010-12
- **Final completion:** 2013-02
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** data analysis showed insufficient drug efficacy
- **Last updated:** 2013-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00406276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00406276, "Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00406276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*